CN102046791B - 表达载体 - Google Patents

表达载体 Download PDF

Info

Publication number
CN102046791B
CN102046791B CN2009801205839A CN200980120583A CN102046791B CN 102046791 B CN102046791 B CN 102046791B CN 2009801205839 A CN2009801205839 A CN 2009801205839A CN 200980120583 A CN200980120583 A CN 200980120583A CN 102046791 B CN102046791 B CN 102046791B
Authority
CN
China
Prior art keywords
plasmid
dna
bifidobacterium
gene
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2009801205839A
Other languages
English (en)
Chinese (zh)
Other versions
CN102046791A (zh
Inventor
嶋谷-柴田裕子
清水瞳
米仓弘美
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kagoshima University NUC
Original Assignee
Anaeropharma Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anaeropharma Science Inc filed Critical Anaeropharma Science Inc
Publication of CN102046791A publication Critical patent/CN102046791A/zh
Application granted granted Critical
Publication of CN102046791B publication Critical patent/CN102046791B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2009801205839A 2008-04-17 2009-04-16 表达载体 Active CN102046791B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12452808P 2008-04-17 2008-04-17
US61/124,528 2008-04-17
PCT/JP2009/001768 WO2009128272A1 (en) 2008-04-17 2009-04-16 Expression vector

Publications (2)

Publication Number Publication Date
CN102046791A CN102046791A (zh) 2011-05-04
CN102046791B true CN102046791B (zh) 2013-09-18

Family

ID=40792658

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2009801205839A Active CN102046791B (zh) 2008-04-17 2009-04-16 表达载体
CN2009801205843A Active CN102046190B (zh) 2008-04-17 2009-04-17 用于缺氧疾病的治疗剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2009801205843A Active CN102046190B (zh) 2008-04-17 2009-04-17 用于缺氧疾病的治疗剂

Country Status (12)

Country Link
US (3) US8383398B2 (enExample)
EP (2) EP2274422B1 (enExample)
JP (3) JP5735804B2 (enExample)
KR (3) KR101674977B1 (enExample)
CN (2) CN102046791B (enExample)
CA (2) CA2721653C (enExample)
DK (2) DK2274422T3 (enExample)
ES (2) ES2628378T3 (enExample)
HU (2) HUE033561T2 (enExample)
PL (2) PL2274422T3 (enExample)
PT (2) PT2274422T (enExample)
WO (2) WO2009128272A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8535939B2 (en) 2010-01-29 2013-09-17 Anaeropharma Science, Inc. Transfection vector
US20130095072A1 (en) * 2010-01-29 2013-04-18 Anaeropharma Science, Inc. Therapeutic agent for ischemic diseases
EP2274422B1 (en) * 2008-04-17 2017-03-15 Anaeropharma Science, Inc. Expression vector
US9730968B2 (en) 2008-04-17 2017-08-15 Anaeropharma Science, Inc. Therapeutic agent for ischemic diseases
US8338162B2 (en) * 2009-04-17 2012-12-25 Anaeropharma Science, Inc. Obligately anaerobic mutant lactic acid bacterium and preparation method therefor, and expression vector functioning in obligately anaerobic lactic acid bacterium
WO2013008881A1 (ja) * 2011-07-13 2013-01-17 株式会社アネロファーマ・サイエンス 虚血性疾患治療薬
KR20170088866A (ko) 2014-12-03 2017-08-02 가부시키가이샤 아네로파마·사이엔스 공발현 플라스미드
KR101892722B1 (ko) * 2015-01-19 2018-08-28 고쿠리츠 다이가쿠 호우징 신슈 다이가쿠 허혈성 질환 치료제
LU100900B1 (de) * 2018-08-10 2020-02-17 Thomas Melchior Homann Verbindungen zur modulation von a-ketoglutarsäure (2kg)-abhängigen oxygenasen
WO2021038975A1 (ja) 2019-08-28 2021-03-04 株式会社アネロファーマ・サイエンス ダイアボディ型ＢｓＡｂを発現・分泌するビフィドバクテリウム属細菌
CN112999215B (zh) * 2019-12-20 2024-06-21 复旦大学 呋喃酮糖苷类化合物的应用
CN115400154A (zh) * 2022-08-10 2022-11-29 深圳未知君生物科技有限公司 长双歧杆菌在制备治疗自闭症谱系障碍的药物中的应用
WO2024187069A1 (en) * 2023-03-08 2024-09-12 University Of Florida Research Foundation, Incorporated Engineering enterobacteria to site-specifically activate the anticancer prodrug 5-fluorocytosine for treating colon cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020054865A1 (en) * 2000-09-21 2002-05-09 Minoru Fujimori Anaerobic bacterium as a drug for cancer gene therapy
WO2007136107A1 (ja) * 2006-05-24 2007-11-29 Anaeropharma Science Inc. 遺伝子輸送担体作製方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8713601D0 (en) * 1987-06-10 1987-07-15 Unilever Plc Fermentation
WO1991009131A1 (en) * 1989-12-20 1991-06-27 Valio Finnish Cooperative Dairies Association Cloning vector for use in lactic acid bacteria
US6984513B2 (en) 1994-03-03 2006-01-10 The Board Of Trustees Of The Leland Stanford Junior University Anaerobe targeted enzyme-mediated prodrug therapy
US6416754B1 (en) 1994-03-03 2002-07-09 The Board Of Trustees Of The Leland Stanford Junior University Anaerobe targeted enzyme-mediated prodrug therapy
TW357191B (en) * 1996-06-04 1999-05-01 Food Industry Development Res Institute Bifidobacteria strains with acid, bile salt and oxygen tolerance and their culture method the invention relates to bifidobacteria strains with acid, bile salt and oxygen tolerance and their culture method
JP2000060541A (ja) * 1998-08-27 2000-02-29 Fuyuki Mitsuyama ビフィズス菌増殖促進物質と整腸物質とビフィズス菌製剤
JP3642755B2 (ja) 2000-09-21 2005-04-27 純 天野 嫌気性菌を用いた遺伝子治療用医薬
US7008633B2 (en) * 2000-12-18 2006-03-07 Board Of Regents, The University Of Texas System Local regional chemotherapy and radiotherapy using in situ hydrogel
KR100457879B1 (ko) * 2001-02-24 2004-11-18 주식회사 비피도 비피도박테리움 유래 신규 플라스미드, 이를 이용한 재조합 발현 벡터 및 형질전환 방법
PT2088193E (pt) 2004-11-24 2011-02-24 Anaeropharma Science Inc Novo vector vaivém
ES2548516T3 (es) * 2005-01-21 2015-10-19 The Research Foundation Of The State University Of New York Métodos para el tratamiento de la capsulitis adhesiva
EP1867714B1 (en) 2005-04-08 2013-09-18 Anaeropharma Science Inc. 5-fluorouracil-resistant bacteria and method for production thereof
CA2646244A1 (en) * 2006-03-27 2007-10-04 Government Of The United States Of Americas, As Represented By The Secre Tetracycline compounds and methods of treatment
GB2439310A (en) * 2006-04-13 2007-12-27 Ambrozea Inc Fermentation residuals from genetically-modified microorganisms
EP2274422B1 (en) * 2008-04-17 2017-03-15 Anaeropharma Science, Inc. Expression vector

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020054865A1 (en) * 2000-09-21 2002-05-09 Minoru Fujimori Anaerobic bacterium as a drug for cancer gene therapy
WO2007136107A1 (ja) * 2006-05-24 2007-11-29 Anaeropharma Science Inc. 遺伝子輸送担体作製方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Corneau N等.Molecular characterization of three plasmids from Bifidobacterium longum.《Plasmid》.2004,第51卷(第2期),87-100. *

Also Published As

Publication number Publication date
CN102046190A (zh) 2011-05-04
EP2274422B1 (en) 2017-03-15
US20110110893A1 (en) 2011-05-12
KR20160102584A (ko) 2016-08-30
JP5514735B2 (ja) 2014-06-04
JP2011518112A (ja) 2011-06-23
EP2280717A1 (en) 2011-02-09
PT2280717T (pt) 2018-10-04
WO2009128275A9 (en) 2010-11-11
CA2721664A1 (en) 2009-10-22
CA2721653A1 (en) 2009-10-22
PT2274422T (pt) 2017-06-28
EP2274422A1 (en) 2011-01-19
CN102046791A (zh) 2011-05-04
JP6089025B2 (ja) 2017-03-01
US8470311B2 (en) 2013-06-25
ES2686080T3 (es) 2018-10-16
CA2721653C (en) 2018-03-20
CA2721664C (en) 2018-01-23
CN102046190B (zh) 2013-03-13
US20090264513A1 (en) 2009-10-22
WO2009128275A4 (en) 2010-02-18
JP2015091243A (ja) 2015-05-14
KR101674977B1 (ko) 2016-11-10
US20130122582A1 (en) 2013-05-16
DK2274422T3 (en) 2017-07-03
PL2280717T3 (pl) 2018-10-31
WO2009128272A1 (en) 2009-10-22
WO2009128275A1 (en) 2009-10-22
DK2280717T3 (en) 2018-09-10
KR20100134765A (ko) 2010-12-23
JP2011517929A (ja) 2011-06-23
PL2274422T3 (pl) 2017-09-29
EP2280717B1 (en) 2018-05-30
HUE039768T2 (hu) 2019-02-28
KR101671283B1 (ko) 2016-11-02
WO2009128272A4 (en) 2010-02-18
KR20110021784A (ko) 2011-03-04
US8383398B2 (en) 2013-02-26
WO2009128272A9 (en) 2010-11-11
HUE033561T2 (hu) 2017-12-28
JP5735804B2 (ja) 2015-06-17
ES2628378T3 (es) 2017-08-02

Similar Documents

Publication Publication Date Title
CN102046791B (zh) 表达载体
CN102741407B (zh) 转化用质粒
CA2652689C (en) Method of constructing gene transport support

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CP02 Change in the address of a patent holder
CP02 Change in the address of a patent holder

Address after: Tokyo, Japan, Japan Millennium Dai Tian District, Shen Tian Shen Bao 1-103 Tokyo garden tower 201

Patentee after: Anaeropharma Science, Inc.

Address before: All of central Tokyo Japan

Patentee before: Anaeropharma Science, Inc.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20210604

Address after: Washington, USA

Patentee after: Asusa Medical Sciences Ltd.

Address before: Tokyo, Japan, Japan Millennium Dai Tian District, Shen Tian Shen Bao 1-103 Tokyo garden tower 201

Patentee before: Anaeropharma Science, Inc.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20250304

Address after: The Japanese city of Kagoshima

Patentee after: KAGOSHIMA University

Country or region after: Japan

Address before: Washington, DC

Patentee before: Asusa Medical Sciences Ltd.

Country or region before: U.S.A.